A Long-Term Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Biosplice Therapeutics
- 15 Jun 2024 Results reporting radiographic and pain outcomes, long-term data and repeated usage of Lorecivivint in patients with severe knee osteoarthritis presented at the 25th Annual Congress of the European League Against Rheumatism
- 15 Jun 2024 Results of an analysis assessing long-term, repeated usage of Lorecivivint in patients with severe knee OA as assessed by PASS presented at the 25th Annual Congress of the European League Against Rheumatism
- 18 Apr 2024 Results published in a Biosplice Therapeutics media release